-
PLGA Microspheres for Controlled Corticosteroid Delivery
2026-09-15
A 2026 Pharmaceutics study shows that PLGA microsphere size, surface chemistry, and corticosteroid stability jointly determine performance in cartilage delivery. Its findings distinguish apparent diffusion-model fit from the steric constraints of the collagen network and identify PEGylation as a strategy for preserving hydrocortisone-17-butyrate during release.
-
ZK53: A Metabolic Stress Map for ClpP Research
2026-09-15
ZK53 is a selective human mitochondrial serine protease ClpP activator that converts mitochondrial proteostasis failure into measurable cancer-cell stress. This guide connects ClpP activation with translatome-aware assay design, oxidative phosphorylation disruption, DNA-damage signaling, and ferroptosis sensitivity.
-
PD 0332991 in Gastric Cancer Assembloid Assays
2026-09-14
Use PD 0332991 (Palbociclib HCl) to connect CDK4/6 biology with patient-derived gastric cancer organoid and assembloid testing. This workflow separates tumor-cell sensitivity from stromal protection, enabling more informative G1-arrest, Rb signaling, and viability measurements.
-
mRNA Vaccine Memory: Antigen Versus LNP Immunity
2026-09-14
The reference study presents SAPC-LNPs, a sialic acid– and cleavable-PEG-modified delivery system designed to strengthen antigen-specific immune memory while limiting immune memory against the nanoparticle carrier. In a mouse cancer-vaccine setting, this balance was associated with improved endosomal escape, fewer formulation-related effects, and more durable antitumor protection after repeated administration.
-
Oridonin, Inflammation, and Esophageal Cancer
2026-09-13
Peng et al. investigated whether oridonin can counter esophageal cancer-associated inflammation through the TLR4/NF-κB/NLRP3 inflammasome axis in a 4-nitroquinoline N-oxide mouse model. The integrated pathology, hematology, cytokine, qPCR, and western blot findings support pathway-linked anti-inflammatory activity, while the preclinical design does not yet establish direct molecular causality or clinical efficacy.
-
Bismuth Subsalicylate in GI Assay Design
2026-09-12
Bismuth Subsalicylate can do more than support gastrointestinal disorder research when its chemical behavior, prostaglandin pathway activity, and membrane-based apoptosis readouts are interpreted together. This article presents an orthogonal assay strategy grounded in product specifications and annexin V methodology.
-
iRhom2, Olfactory Receptors, and Sensory Adaptation
2026-09-12
Azzopardi and colleagues identify iRhom2 as a previously underappreciated regulator in olfactory sensory neurons, linking odorant receptor expression with activity-dependent adaptation. Their combination of knockout analysis, transcriptomics, spatial validation, and receptor signaling experiments supports an iRhom2/ADAM17 feedback model while also defining important limits for mechanistic interpretation.
-
Recombinant Mouse SHH in Comparative Morphogenesis
2026-09-11
Discover how Recombinant Mouse Sonic Hedgehog and the P1230 SHH protein can turn comparative embryology into a causal, stage-aware assay strategy. This guide connects product biology with evidence from mouse–guinea pig genital development and practical experimental design.
-
T-5224: Mapping AP-1 in Inflammation Assays
2026-09-11
T-5224 is a selective C-Fos/AP-1 inhibitor for dissecting inflammatory and osteoclastogenic transcription. This article explains how to use it as a causal assay perturbation, including a carefully bounded comparison with microbial extracellular-vesicle signaling in cancer research.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-10
The reference study identifies circulating moesin as a candidate indicator of endothelial injury and sepsis severity, linking higher serum levels with SOFA scores, procalcitonin, pulmonary permeability, and lung damage. By combining patient samples, LPS and cecal ligation and puncture models, and endothelial-cell silencing experiments, the work also implicates the ROCK1/MLC and NF-κB pathways in moesin-associated barrier dysfunction.
-
Talin1–Piezo1–YAP Axis in Atherosclerosis
2026-09-10
A 2026 study identifies Talin1 as a mechanistic link between Piezo1-dependent calcium influx, YAP activity, and inflammatory endothelial behavior under atherosclerosis-associated stress. By combining an ApoE-knockout mouse model with TNF-α and oscillatory-shear-stress experiments in endothelial cells, the work positions Talin1 as a potential target for more selective vascular anti-inflammatory strategies.
-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-09-09
A 2025 Nature Metabolism study identifies intestinal TM6SF2 as a protective regulator of the gut–liver axis, linking epithelial lipid handling to barrier integrity, microbial composition and hepatic lysophosphatidic acid signaling. Its conditional knockout, fecal-transfer, co-housing and pharmacological experiments provide a mechanistic framework for understanding how intestinal dysfunction can initiate MASH beyond the liver itself.
-
Cisplatin Workflows for Cancer Research
2026-09-09
Build more informative CDDP experiments by connecting DNA damage, apoptosis, oxidative stress, and chemotherapy resistance readouts in one workflow. Extend conventional viability testing into macrophage–tumor studies and tumor growth inhibition in xenograft models with practical handling and troubleshooting guidance.
-
Pregnenolone Carbonitrile: PXR Workflow Guide
2026-09-08
Pregnenolone Carbonitrile is a practical rodent PXR agonist for connecting cytochrome P450 CYP3A induction with hepatic detoxification and liver fibrosis assays. This workflow also translates a recent PXR–AVP discovery into controlled water-homeostasis experiments while separating established applications from emerging biology.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody for HMGB1
2026-09-08
Learn how the FITC Goat Anti-Rabbit IgG (H+L) Antibody supports fluorescent validation of HMGB1 and other rabbit-primary-antibody assays. This guide connects quantitative proteomic discovery with practical immunofluorescence, flow cytometry, and tissue-detection decisions.